This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cynata Therapeutics Limited
Drug Names(s): mesenchymal stem cells (MSCs)
Description: CYP-001 is an induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product. Cynata's proprietary Cymerus technology utilizes iPSCs to produce particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus platform provides a source of MSCs that is independent of donor limitations and provides an “off-the-shelf” stem cell platform for therapeutic product use.
Cynata and Fujifilm
In September 2016, Cynata Therapeutics announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynatas lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. Pursuant to the term sheet, the parties will work together to seek to finalise a definitive agreement. If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016.
The term sheet anticipates that, under a definitive agreement, Cynata will grant FUJIFILM an option to an exclusive, worldwide licence to market and sell Cynatas lead MSC product for prevention and treatment of graft-versus-host disease (GvHD), as well as (a) an option to negotiate a licence for manufacturing those products, and (b) certain rights to Cynatas proprietary Cymerus technology for the prevention and treatment of...See full deal structure in Biomedtracker
Additional information available to subscribers only: